



Up to \$240 Million
Private Placement



Lead Placement Agent
January 2024

Leerink Partners Serves as Lead Placement Agent for Immunic's (Nasdaq: IMUX) Up to \$240 Million Private Placement

Key Transaction Highlights

- Three-tranche private placement of up to \$240 million in gross proceeds that priced on January 5
- First tranche of \$80 million at a price of \$1.43 per share
- Second tranche of \$80 million at a price of \$1.716 per share, subject to the satisfaction of certain conditions
- Third tranche of \$80 million at a price of \$1.716 per share, subject to the satisfaction of certain conditions
- Immunic intends to use the net proceeds from the private placement to fund the ongoing clinical development of its three lead product candidates, vidofludimus calcium (IMU-838), IMU-856 and IMU-381, and for other general corporate purposes.
- The financing was led by BVF Partners L.P., and included participation from new and existing investors, including Avidity Partners, Janus Henderson Investors, Soleus Capital, RTW Investments and Adage Capital Partners LP.
- This is Leerink Partners' 3rd equity transaction for Immunic and 2nd equity offering in 2024.

If you would like to unsubscribe from this distribution, click [here](#).

THIS EMAIL IS FOR INFORMATIONAL PURPOSES ONLY AND IS BEING FURNISHED TO INVESTMENT BANKING CLIENTS OF LEERINK PARTNERS LLC. THE INFORMATION INCLUDED HEREIN IS FOR YOUR INFORMATION ONLY AND MAY NOT BE REPRODUCED FOR OR REDISTRIBUTED TO ANY OTHER PURPOSES. THESE SECURITIES HAVE BEEN SOLD. THIS EMAIL IS NOT AN OFFER TO SELL, AND IS NOT SOLICITING AN OFFER TO BUY, ANY SECURITIES.

BOSTON
53 State Street
40th Floor
Boston, MA 02109

CHARLOTTE
2151 Hawkins Street
Suite 1025
Charlotte, NC 28203

MIAMI
1395 Brickell Avenue
Suite 800
Miami, FL 33131

NASHVILLE
40 Burton Hills Boulevard
Suite 200
Nashville, TN 37215

NEW YORK
1301 Avenue of the Americas
12th Floor
New York, NY 10019

SAN FRANCISCO
255 California Street
12th Floor
San Francisco, CA 94111